61160-18-7

Basic information

• Product Name: 3-(BENZYLOXY)-2-METHYL-4(1H)-PYRIDINONE
• Synonyms: 3-BENZYLOXY-2-METHYL-1H-PYRIDIN-4-ONE;3-(BENZYLOXY)-2-METHYL-4(1H)-PYRIDINONE;4(1H)-Pyridinone, 2-methyl-3-(phenylmethoxy)-;3-(Benzyloxy)-2-Methylpyridin-4(1H)-one
• CAS NO: 61160-18-7
• Molecular Formula: C₁₃H₁₃NO₂
• Molecular Weight: 215.25
• Mol File: 61160-18-7.mol
• Article Data: 25

Chemical Properties

• Melting Point: 171-173°C
• Boiling Point: 389.5 °C at 760 mmHg
• Flash Point: 189.3 °C
• Appearance: /
• Density: 1.17 g/cm³
• Vapor Pressure: 2.85E-06mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-(BENZYLOXY)-2-METHYL-4(1H)-PYRIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(BENZYLOXY)-2-METHYL-4(1H)-PYRIDINONE(61160-18-7)
• EPA Substance Registry System: 3-(BENZYLOXY)-2-METHYL-4(1H)-PYRIDINONE(61160-18-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 61160-18-7(Hazardous Substances Data)

Usage

Description

3-(Benzyloxy)-2-methyl-4(1H)-pyridinone is a pyridinone derivative with the molecular formula C13H13NO2. It features a benzyl ether group and a methyl group on the pyridinone ring, which contribute to its potential pharmacological properties. This versatile chemical compound has been studied for its antitumor activity and its capacity to inhibit DNA topoisomerase II, making it a promising candidate for medicinal applications. Additionally, it has been investigated for its use in the synthesis of various organic compounds, highlighting its significance in synthetic chemistry.

Uses

Used in Pharmaceutical Industry:
3-(Benzyloxy)-2-methyl-4(1H)-pyridinone is used as an antitumor agent for its potential to combat cancer cells. Its ability to inhibit DNA topoisomerase II, an enzyme that plays a crucial role in DNA replication, contributes to its antitumor properties, making it a valuable compound in the development of cancer therapeutics.
Used in Medicinal Chemistry Research:
3-(Benzyloxy)-2-methyl-4(1H)-pyridinone serves as a key intermediate in the synthesis of various organic compounds with potential medicinal applications. Its unique structure allows for further chemical modifications, enabling the development of new drugs with improved pharmacological profiles.
Used in Synthetic Chemistry:
3-(Benzyloxy)-2-methyl-4(1H)-pyridinone is utilized as a building block in the synthesis of complex organic molecules. Its presence in the molecular structure facilitates the formation of new chemical entities, broadening the scope of synthetic chemistry and contributing to the discovery of novel compounds with diverse applications.

InChI:InChI=1/C13H13NO2/c1-10-13(12(15)7-8-14-10)16-9-11-5-3-2-4-6-11/h2-8H,9H2,1H3,(H,14,15)

Upstream product

• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 61049-69-2 3-O-benzylmaltol 
• 118-71-8 Maltol 

Downstream Products

• 82756-32-9 3-(benzyloxy)-1-hexyl-2-methylpyridin-4(1H)-one 
• 17184-19-9 3-hydroxy-2-methylpyrid-4-one 
• 127234-69-9 2-methyl-3,4-di(benzyloxy)pyridine 
• 174095-91-1 2-methyl-3-benzyloxy-5-(N,N-dimethyl)aminomethyl-pyridin-4-one 
• 848644-93-9 C₆₉H₆₀N₆O₉ 
• 848644-94-0 C₆₆H₆₃N₇O₉ 
• 848644-95-1 3,4-bis-benzyloxy-pyridine-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester 
• 718596-13-5 3,4-dibenzyloxypyridine-2-carboxy-N-(2-hydroxyethyl)amide 
• 349141-25-9 2-carboxy-3,4-di(benzyloxy)pyridine 
• 127234-85-9 2-hydroxymethyl-3,4-di(benzyloxy)pyridine 
• 127234-70-2 2-methyl-3,4-di(benzyloxy)pyridine N-oxide 
• 143946-79-6 2-formyl-3,4-di(benzyloxy)pyridine 
• 654054-81-6 (1'R,4'S)-1-[5'-tert-butyldiphenylsilyl-2',3'-dideoxy-β-D-ribofuranosyl]-2-methyl-3-benzyloxy-4-pyridinone 
• 654054-82-7 (1'S,4'S)-1-[5'-tert-butyldiphenylsilyl-2',3'-dideoxy-α-D-ribofuranosyl]-2-methyl-3-benzyloxy-4-pyridinone 

Relevant articles and documents

Coumarin heterozygous pyridone compounds having iron chelation and monoamine oxidase B inhibitory activity as well as preparation and application of compounds

The invention discloses coumarin/pyridone heterozygous derivatives represented by a formula (I) shown in the description or a pharmaceutically-acceptable salt of the derivatives. The preparation method of the coumarin/pyridone heterozygous derivatives comprises the following steps: one pyridone derivative represented by a formula 3 shown in the description is obtained by a series of synthesis by using one hydroxypyrone with different substituent groups represented by a formula 1 shown in the description as a raw material; and a compound represented by a formula 4 shown in the description is subjected to a condensation reaction to obtain a compound represented by a formula 5 shown in the description, one-step bromination is performed to obtain a compound represented by a formula 6 shown inthe description, the compound represented by the formula 6 and the pyridone derivative represented by the formula 3 are subjected to a one-step nucleophilic substitution reaction to obtain a compoundrepresented by a formula 7 shown in the description, and finally an alkyl protecting group in a pyridone structure is removed to obtain one target compound represented by the formula (I). The compounds provided by the invention are a novel series of single-molecular multi-target series drugs, and have iron chelation, targeted MAO-B inhibitory activity, antioxidant activity, unique advantages for an Alzheimer disease with complicated pathogenesis, a clear mechanism of action and excellent activity.

Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles

This work is a continuation of our initial discovery of a potent monocyclic carbamoyl pyridone human immunodeficiency virus type-1 (HIV-1) integrase inhibitor that displayed favorable antiviral and pharmacokinetic properties. We report herein a series of

Prediction of 3-hydroxypyridin-4-one (HPO) log K1 values for Fe(iii)

As a means to aid in the design of 3-hydroxypyridin-4-ones (HPOs) intended for use as therapeutic Fe3+ chelating agents, a novel methodology has been developed using quantum mechanical (QM) calculations for predicting the iron binding affinities of the compounds (more specifically, their log K 1 values). The reported/measured HPO log K1 values were verified through their correlation with the corresponding sum of the compounds' ligating group pKa values. Using a training set of eleven HPOs with known log K1 values, reliable predictions are shown to be obtained with QM calculations using the B3LYP/6-31+G(d)/CPCM model chemistry (with Bondi radii, and water as solvent). With this methodology, the observed log K 1 values for the training set compounds are closely matched by the predicted values, with the correlation between the observed and predicted values giving r2 = 0.9. Predictions subsequently made by this method for a test set of 42 HPOs of known log K1 values gave predicted values accurate to within ±0.32 log units. In order to further investigate the predictive power of the method, four novel HPOs were synthesised and their log K1 values were determined experimentally. Comparison of these predicted log K1 values against the measured values gave absolute deviations of 0.22 (13.87 vs. 14.09), 0.02 (14.31 vs. 14.29), 0.12 (14.62 vs. 14.50), and 0.13 (15.04 vs. 15.17). The prediction methodology reported here is the first to be provided for predicting the absolute log K1 values of iron-chelating agents in the absence of pKa values.